ZIA CP010124 10541 (ZIA) | |||
---|---|---|---|
Title | HPV Seroepidemiology for Anogenital Cancers | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Wentzensen, Nicolas | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $22,094 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Cervical Cancer (50.0%) Vaginal (50.0%) |
||
Research Type | |||
Cancer-Related Biology
Exogenous Factors in the Origin and Cause of Cancer |
|||
Abstract | |||
Previous serology assays were inaccurate and limited to a very few HPV types; hence we stopped using HPV serology in our natural history studies. A multiplex assay developed by Michael Pawlita can test for seroconversion for 37 HPV antigens from the 8 most carcinogenic HPV types and the two HPV genotypes that cause 90% of genital warts. Antibodies against viral capsid proteins, especially L1, are associated with HPV infection while antigens directed against the HPV oncoproteins E6 and E7 are more associated with cancer. Early published validation studies have been very promising, showing strong associations of HPV6 with genital warts and HPV16 with cervical neoplasia. We are currently utilizing these advanced methods to examine the relationships of L1 versus E6/E7 seroconversion to a variety of anogenital tumors, using samples from a variety of completed case-control studies. The multiplex assay is very fast and inexpensive compared to the old, single-antigen ELISAs. |